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Abstract CXCR4 and its ligand CXCL12 can promote the
proliferation, survival, and invasion of cancer cells. They have
been shown to play an important role in regulating metastasis
of breast cancer to specific organs. High CXCR4 expression
was also correlated to poor clinical outcome. Previous study
also showed that tumor cells express a high level of CXCR4
and that tumor metastasis target tissues (lung, liver, and bone)
express high levels of the ligand CXCL12, allowing tumor
cells to directionally migrate to target organs via a CXCL12-
CXCR4 chemotactic gradient. However, the exact mecha-
nisms of how CXCR4 and CXCL12 enhance metastasis
and/or tumor growth and their full implications on breast
cancer progression are unknown. Yet it is likely that chemo-
kine receptor signaling may provide more than just a migra-
tional advantage by also helping the metastasized cells estab-
lish and survive in secondary environments. In this study, we
investigated CXCR4 and CXCL12 expression in breast can-
cer and analyzed its association with clinicopathological fac-
tors by immunohistochemistry first. Then, we detected the
mRNA and protein expression of CXCR4 and CXCL12 in
breast cancer cell lines by Western blot and RT-PCR. The
MDA-MB-231 has CXCR4 expression and very weak
CXCL12 expression. So, we constructed the functional
CXCL12 expression in MDA-MB-231 using a gene
transfection technique. Further experiments were conducted
to evaluate the effect of CXCL12 transfection on the biolog-
ical behaviors of MDA-MB-231. The cell proliferation of
MDA-MB-231–CXCL12 was accessed by MTT assay; the
apoptosis was analyzed by an AnnexinV-FITC/propidium
iodide double staining of flow cytometry method; and the cell
invasive ability was examined by Matrigel invasion assay.
Immunohistochemical analysis showed the co-expression of
CXCR4 and CXCL12 correlated with lymph node metastasis
and TNM stage (p<0.01). It suggested that the chemokine
CXCL12 and its sole ligand CXCR4 play important role in the
malignance of breast cancer. To gain a deeper insight into it,
we picked CXCR4-expressing cells MDA-MB-231 to be
transfected with CXCL12 stably. The decreased cellular pro-
liferation, increased apoptosis, and invasive ability were found
in MDA-MB-231 with successful CXCL12 transfection
(p<0.05). Our findings underlined the CXCL12-CXCR4 axis
correlated tightly with breast cancer metastasis. CXCL12-
CXCR4 axis can increase the invasion and apoptosis of
MDA-MB-231 simultaneously. These data strongly support
the hypothesis that CXCL12-CXCR4 axis promotes the nat-
ural selection of breast cancer cell metastasis. Our findings
could have significant implications in terms of breast cancer
aggressiveness and the effectiveness of targeting the receptors
and downstream signaling pathways for the treatment of
breast cancer.
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Introduction
Breast cancer is one of the most common malignancies and
the first leading cause of death and disability among women,
especially young women, in low- and middle-income coun-
tries [1, 2]. Metastatic breast cancer remains the chief cause of
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cancer-related death among women. In tumor growth and
metastasis, chemokines and their receptors have a multiface-
ted effect for regulating angiogenesis, tumor cell proliferation,
and apoptosis, mediating tumor cell metastasis in an organ-
specific manner [3]. Several groups found that CXCR4 and its
ligand CXCL12 can promote the proliferation, survival, and
invasion of cancer cells [4–6]. There are evidences that tumor
cells express a high level of CXCR4 and that tumor metastasis
target tissues (lung, liver, and bone) express high levels of the
ligand CXCL12, allowing tumor cells to directionally migrate
to target organs via a CXCL12-CXCR4 chemotactic gradient
[7–9]. Previous study also showed the disruption of the
CXCL12-CXCR4 signaling axis specifically in transformed
tissue via epigenetic silencing of the chemokine ligand in
colorectal carcinoma cells [10–13]. How about the role of
CXCL12-CXCR4 signaling axis in breast cancer metastasis?
In the present study, we investigated CXCL12 and CXCR4
expression in breast cancer and further to analyze its role in
survival and invasive ability of breast cancer cells.
Materials and methods
Patients and tissues
Breast cancer tissue samples (n=182) were obtained from
surgical resection in the Department of Breast Surgical, the
First Affiliated Hospital of China Medical University (China)
between January 2007 and February 2013. Patients’ ages at
the time of surgery ranged from 26 to 65, with an average age
of 45.9 years old. Pathology classification was based on the
WHO criteria published by Tavassoli et al. [14–16]. None of
the patients received neoadjuvant chemotherapy or radiother-
apy before operation. Clinicopathological information of each
patient was reviewed using the hospital medical records.
Ethics statement
The study protocol was reviewed and approved by the Ethics
Committee of ChinaMedical University (Shenyang, China) and
of the participating hospital (the First Affiliated Hospital of
China Medical University, Shenyang, China). All patients en-
rolled in this study have signed an informed consent form to
agree to participate in this study and for publication of the
results.
Immunohistochemical staining
Formalin-fixed and paraffin-embedded specimens were cut into
4-μm-thick sections, which were subsequently dewaxed and
hydrated. Immunohistochemical staining for CXCL12 (sc-
28876, 1:100, Santa Cruz, USA) and CXCR4 (sc-53534,
1:500, Santa Cruz, USA) was performed using
UltraSensitive™ S-P kits (Maixin-Bio, China) according to
the manufacturer's instructions and using the reagent supplied
with the kit. For the negative control, phosphate-buffered saline
(PBS) was used in place of the primary antibodies. We adopted
the German semi-quantitative scoring system in considering the
staining intensity and area extent, which has been widely ac-
cepted and used in previous studies [17, 18]. Every lesions was
given a score according to the intensity of the staining (no
staining = 0, weak staining = 1, moderate staining = 2, strong
staining = 3) and the extent of stained cells (0 %=0, 1–10%=1,
11–50 %=2, 51–80 %=3, 81–100 %=4; negative means 0 %
area staining). The final immunoreactive score was determined
by multiplying the intensity scores with the extent of positivity
scores of stained cells, with the minimum score of 0 and a
maximum score of 12 [17, 18]. Slides were independently
examined by two pathologists. However, if there was a discrep-
ancy in individual scores, both pathologists reevaluated together
by reaching a consensus agreement before combining the indi-
vidual scores. To obtain statistical results, a final score equal to
or less than 1 was considered as negative, while scores of 2 or
more were considered as positive.
Breast cancer cell lines and cell culture conditions
Breast cancer cell lines including MCF-7 (low metastatic
potential), MDA-MB-435s andMDA-MB-231 (high metasta-
tic potential) were chosen for this study. They are all obtained
from the American Tissue Culture Collection (Manassas,
USA), and were stored in the laboratory of the Pathology
Department, the First Affiliated Hospital and College of
Basic Medical Sciences of China Medical University
(Shenyang, China). The cells were cultured in RPMI 1640
medium (Gibco, USA) supplemented with 10 % fetal bovine
serum (FBS) (Hyclone, USA) in a 5 % CO2 humidified
atmosphere at 37 °C.
Western blot analyses and reverse transcription-PCR
(RT-PCR) analyses
The breast cells of MCF-7, MDA-MB-435s, and MDA-MB-
231 were washed with ice-cold phosphate-buffered saline and
then lysed in lysis buffer containing 10 mM Tris (pH 7.5),
150 mM NaCl, 10 mM ethylenediaminetetraacetic acid
(EDTA), 1 % sodium dodecyl sulfate (SDS), 1 mM sodium
orthovanadate, and a mixture of protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 1 μg/mL pepstatin A, 2 μg/
mL aprotinin). The lysates were sonicated for 10 s, centrifuged
for 20 min at 20,000×g and then stored at −70 °C. Equal
amounts (25 μg) of the cell lysates were resolved by 12 %
SDS-PAGE and transferred to polyvinylidene fluoride mem-
branes. After blocking, blots were incubated with mouse anti-
CXCR4 monoclonal antibody (sc-53534, Santa Cruz, 1:500),
rabbit anti-CXCL12 polyclonal antibody CXCL12 (sc-28876,
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1:200, Santa Cruz, USA), or β-actin (Zhongshan Golden
Bridge Biotechnology, 1:1000) overnight at 4 °C and followed
by each corresponding second antibody at room temperature for
1 h at 37 °C. Then, the results developed by ECL (Pierce
Biotechnology, USA). The protein bands were then analyzed
using the BioImaging System (UVP, USA). The grayscale
values of the CXCL12 and CXCR4 were normalized to the
values of the corresponding β-actin band to determine the
expression level of the protein. The experiments were repeated
at least three times independently. Total RNA from MCF-7,
MDA-MB-435s, and MDA-MB-231 was extracted with
TRIzol reagent (Invitrogen, USA), and the quality of RNA
was analyzed by A260/A280 ratio and gel analysis. The reverse
transcription was performed with RNA PCR kit (AMV ver.3.0,
Takara, Japan) according to the manufacturer's protocols. The
sequences of primers used are as follows: CXCL12, forward, 5′-
GTCAGCCTGAGCTACAGATGC-3′ and reverse, 5′-CTTT
AGCTTCGGGTCAATGC-3 and CXCR4, forward, 5′-CCGT
GGCAAACTGGTACTTT-3′ and reverse, 5′-GACGCCAACA
TAGACCACCT-3′. PCR products were electrophoresed on a
2 % agarose gel, and semi-quantitative evaluation of their
mRNA expression levels was performed relative to expression
of the house keeping genes glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). The primers for GAPDH were forward,
5′-CCACCCATGGCAAATTCCCATGGCA-3′ and reverse,
5′-TCTAGACGGCAGGTCAGGTCCACC-3′. The experi-
ments were repeated at least three times independently. The
results showed that mRNA and protein of CXCR4 were ob-
served in MDA-MB-435s and MDA-MB-231, and mRNA and
protein of CXCL12 were obvious in MDA-MB-435s and very
weak in MDA-MB-231. MCF-7 has very weak CXCR4 and
CXCL12 mRNA and protein expression. So, we picked MDA-
MB-231 to be transfected with CXCL12, and further to inves-
tigate the role of CXCL12 in the MDA-MB-231 with CXCR4
expression.
CXCL12 stable transfection
The human full-length CXCL12 cDNA fragment was ligated to
the cloning site of pIRES2-ZsGreen1 (Invitrogen, USA),
followed by transformation using One Shot E.coli (Invitrogen,
USA) verification and amplification. Purified plasmid, or con-
trol plasmid, was used to transfect MDA-MB-231 cells by
electroporation using an electroporator and EasyJet Plus, follow-
ed by selection with G418 (Sigma, Germen). Stable CXCL12
transfectant (MDA-MB-231–CXCL12), or stable control plas-
mid transfectant (MDA-MB-231–ZsGreen1), was subsequently
established and verified (RT-PCR and Western blot).
MTT assay
Cell proliferation of MDA-MB-231–CXCL12 and MDA-
MB-231–ZsGreen1 was assessed at various time points by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT) assay. The wild-type MDA-MB-231 served as the
control. Briefly, 2,000 cells were seeded in each well of a
96-well plate (eight repeats) and allowed to adhere for 8 h.
Then, 5 mg/mlMTT (Sigma, Germen) was added to each well
and incubated for 4 h. The cells were lysed by adding 150 μl/
well of dimethyl sulfoxide and read at 490 nm absorbance
wavelength in microplate reader. The experiments were re-
peated at least three times independently.
Flow cytometry apoptosis assay
Analysis of apoptosis was accessed by an AnnexinV-FITC/
propidium iodide double staining kit (Genmed Bioscience,
China) following the manufacturer’s protocols. Briefly, the
wild-type MDA-MB-231, MDA-MB-231–CXCL12, and
MDA-MB-231–ZsGreen1 were plated in six wells. Of
BVDU, 1 μM was treated. Cells were continuously cultured
for 48 and 72 h, and then to be harvested. Before reading on
the flow cytometer, cell suspensions were washed in PBS,
resuspended with a 1×binding buffer and exposed to 5 μL of
Annexin V-FITC (20 μg/mL) and 10 μL of propidium iodide
(PI; 50 μg/mL). After incubation of 20 min in the dark, the
samples were subjected to a FACScan flow cytometer
[equipped with CellQuest and ModFITLT for Mac V1.01
software (Becton Dickinson, San Jose, CA)]. The experiments
were repeated at least three times independently.
Matrigel invasion assay
Cell invasive ability was examined using a 24-well Transwell
with 8.0-μm pore polycarbonate membrane inserts (Corning
Inc., NY, USA) according to the manufacturer’s protocol. The
Matrigel (100 μl/ml) was applied to the upper surface of the
membranes. After the treatment of transfection for 48 and
72 h, cells of MDA-MB-231–CXCL12 and MDA-MB-231–
ZsGreen were seeded on the upper chamber (5×104 cells/
well) and incubated for 18 h. Cells that had invaded the
surface of the membrane were fixed with methanol and
stained with hematoxylin. The cells that invaded and moved
onto the lower surface of the filter membrane were counted in
10 random high power fields (×400) by an inverted micro-
scope. The experiment was repeated five times, and the data
were shown in mean±standard deviation (SD).
Statistical analysis
SPSS version 13.0 forWindowswas used for all analyses. The
Pearson chi-Square test was used to analyze the relationship
between CXCL12 and CXCR4 expression with clinicopatho-
logical factors in breast cancer. One-way analysis of variance
(ANOVA) was performed to compare data from the densitom-
etry analysis ofMTT, FAS,Western blotting, and RT-PCR and
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Matrigel invasion assay. Statistical significance in this study
was set at p<0.05. All reported p values are two-sided.
Result
Expression of CXCL12 and CXCR4 in breast cancer
The results of IHC revealed the membrane and cytoplasmic
staining of the CXCR4 protein (Fig. 1) and the nuclear and
cytoplasm staining of the CXCL12 protein in breast cancer
(Fig. 1). The positive CXCR4 protein expression was seen in
83/182 (45.6 %) cases of breast cancer and CXCL12 positive
expression in 71/182 (39.0 %) breast cancer cases. The rela-
tionship between CXCL12 and CXCR4 expression and dif-
ferent clinicopathological factors in breast cancer is shown in
Table 1. CXCR4 expression was significantly associated with
lymph node metastasis and TNM stage (0.01<p<0.05), but
not with age, menopausal status, first term birth age, tumor
size, and tumor stage (p>0.05). CXCL12 expression correlat-
ed with TNM stage (0.01<p <0.05). The results of immuno-
histochemistry demonstrated CXCR4 and CXCL12 co-ex-
pression in 27.4% (50/182) breast cancer samples and the
co-expression of CXCR4 and CXCL12 correlated with lymph
node metastasis and TNM stage (p<0.01) (Table 2). It
suggested that the chemokine CXCL12 and its sole ligand
CXCR4 played important role in the malignant of breast
cancer.
The CXCL12 and CXCR4 expression in MDA-MB-435s
and MDA-MB-231
As shown in Fig. 2, the mRNA and protein of CXCR4 were
observed in MDA-MB-435s and MDA-MB-231, CXCL12
expression were observed in MDA-MB-435s, and its expres-
sion was very weak in MDA-MB-231. MCF7 has very weak
CXCR4 and CXCL12 mRNA and protein expression (Fig. 2).
So, we picked MDA-MB-231 to be transfected with
CXCL12.
CXCL12 transfection in MDA-MB-231
MDA-MB-231 was transfected with pIRES2-ZsGreen1 plas-
mid encoding human CXCL12 or empty vector pIRES2-
ZsGreen1 as a control, followed by selection with G418 to
yield a stable CXCL12-expressing cell line (MDA-MB-231–
CXCL12) and a stable control plasmid transfectant (MDA-
MB-231–ZsGreen1). Using Western blot and RT-PCR analy-
sis, CXCL12 protein expression was observed in MDA-MB-
231–CXCL12 cells, but very weak in MDA-MB-231–
Fig. 1 Representative
immunohistochemical staining
for CXCL12 and CXCR4 in
breast cancer. Positive CXCL12
immunostaining was seen in
invasive breast cancer; the
patterns of CXCL12 expression
were mixed nuclear/cytoplasmic
staining. Positive CXCR4
immunostaining was seen in
invasive breast cancer; the
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ZsGreen1 or wild-type MDA-MB-231 cells (Fig. 2). It is
indicated that the stable CXCL12 transfection in MDA-MB-
231was successfully constructed.
Effect of CXCL12 transfection on cell proliferation by MTT
The cell proliferation rate of MDA-MB-231–CXCL12 cells
was markedly lower than that of MDA-MB-231–ZsGreen1 or
wild-type MDA-MB-231 cells at 48, 60, and 72 h (p<0.05) as
shown by the MTT results and proliferation curve (Fig. 3),
indicating that the CXCL12/CXCR4 expression induced the
decreased cellular proliferation.
CXCL12 transfection up-regulated the apoptosis
of MDA-MB-231
We monitored the level of apoptosis induction by FCM. As
shown in Fig. 4, MDA-MB-231 transfected with CXCL12
Table 1 CXCL12 and CXCR4 expression in 182 patients with breast cancer
Characteristics Number CXCL12 expression p value CXCR4 expression p value
Positive Negative Positive Negative
n=71 n=111 n=83 n=99
Age
<45 years 101 40 61 χ2=0.03 50 51 χ2=1.39
≥45 years 81 31 50 p>0.05 33 48 p>0.05
Menopausal status
Premenopausal 135 50 85 χ2=0.85 60 75 χ2=0.28
Postmenopausal 47 21 26 p>0.05 23 24 p>0.05
Tumor size
<2 cm 83 36 47 χ2=1.22 43 40 χ2=2.37
≥2 cm 99 35 6 p>0.05 40 59 0.01<p<0.05
Lymph node metastasis
Negative 112 53 59 χ2=0.35 45 67 χ2=3.21
Positive 70 30 40 p>0.05 38 32 p>0.05
Tumor stage
I + II 140 49 91 χ2=4.10 58 82 χ2=4.26
III + IV 42 22 20 0.01<p<0.05 25 17 0.01<p<0.05
Table 2 Co-expression of
CXCL12 and CXCR4 in
182 patients with breast cancer




<45 years 101 32 69 χ2=2.02
≥45 years 81 18 63 p>0.05
Menopausal status
Premenopausal 135 35 100 χ2=0.63
Postmenopausal 47 15 32 p>0.05
Tumor size
<2 cm 83 19 64 χ2=1.95
≥2 cm 99 31 65 p>0.05
Lymph node metastasis
Negative 112 23 89 χ2=7.03
Positive 70 27 43 p<0.01
Tumor stage
I + II 140 30 110 χ2=11.12
III + IV 42 20 22 p<0.01
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showed different percentage of apoptosis with wild-type
MDA-MB-231 or MDA-MB-231–ZsGreen1 at 48 and 72 h
after transfection. Apoptotic cells ratio of MDA-MB-231–
CXCL12 was present 32.7 % at 48 h and 41.1 % at 72 h after
transfection, which was higher than the MDA-MB-231–
ZsGreen1 (15.0 % at 48 h after transfection, 12.3 % at 72 h
after transfection) or the wild-type MDA-MB-231 group
(13.5 % at 48 h after transfection, 16.8 % at 72 h after
transfection) (p<0.05).
CXCL12 transfection increased invasive ability
of MDA-MB-231
Matrigel invasion assays showed that the invasive ability of
the MDA-MB-231 cell was enhanced with CXCL12 transfec-
tion after the treatment of transfection for 48 and 72 h. The
MDA-MB-231–ZsGreen1 and wild-type MDA-MB-231 had
fewer numbers of cell which invaded onto the lower surfaces
of the Transwell filters than MDA-MB-231–CXCL12
(p<0.05).
Discussion
Breast cancer is a major public problem; according to the
World Health Organization, more than 1.2 million people will
be diagnosed each year with breast cancer worldwide; breast
cancer will be responsible for 3 % of deaths among women
[19, 20]. Over the past decade, reports have demonstrated that
chemokines and their receptors play critical roles in the de-
velopment of cancer, including tumor cell growth, migration,
and immune cells in a tumor [21–24]. Tumormetastasis is also
a non-random, highly organ-specific pathophysiological pro-
cess. A growing body of evidence has indicated that the
chemokine CXCL12 and its cognate receptor CXCR4 have
a critical role in this process [25–27]. One such chemokine is
the ubiquitous CXCL12 which signals via the chemokine
receptors CXCR4. The CXCR4-CXCL12 signaling axis con-
tributes to metastasis and clinical outcomes in many different
Fig. 2 The expression patterns of CXCL12 and CXCR4 in breast cancer
cell lines. Total RNA and proteins were extracted from wild-type MCF-7,
wild-type MDA-MB-435s, wild-type MDA-MB-231, MDA-MB-231–
CXCL12 and MDA-MB-231–ZsGreen1. Then they were subjected to RT-
PCR and western blot analysis, respectively, for CXCL12 and CXCR4.
Both mRNA (a) and protein (b) expression of CXCR4 and very weak
expression of CXCL12 were observed consistently in MDA-MB-231.
CXCR4 and CXCL12 mRNA (a) and protein (b) expression was found
in MDA-MB-435s. MCF-7 has very weak CXCR4 and CXCL12 mRNA
and protein expression (a and b). So we picked MDA-MB-231 to be
transfected with CXCL12. CXCL12 mRNA (a) and protein (b) expression
was observed in MDA-MB-231–CXCL12 cells, but very weak in MDA-
MB-231–ZsGreen1 orwild-typeMDA-MB-231 cells. It is indicated that the
stable CXCL12 transfection inMDA-MB-231was successfully constructed
Fig. 3 The proliferation curve of MDA-MB-231–CXCL12 and MDA-
MB-231–ZsGreen1 was constructed by plotting absorbance against time
using the MTT method. Values represent the mean±SD of five indepen-
dent experiments. The cell proliferation rate of MDA-MB-231–CXCL12
cells was markedly lower than that of MDA-MB-231–ZsGreen1 or wild-
type MDA-MB-231 cells at 48 h, 60 h, and 48 h (p<0.05). *indicates a
statistically significant difference between MDA-MB-231–CXCL12
group and MDA-MB-231–ZsGreen1 group (p<0.05)
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types of solid cancer, including breast cancer [28–33]. This
receptor ligand pair appears to be involved in the directed
migration of cancer cells to sites of metastasis, increased sur-
vival of cancer cells in sub-optimal conditions, and establish-
ment of a tumor promoting cytokine/chemokine network. In
the present study, we demonstrated that the co-expression of
CXCR4 and CXCL12 was correlated with lymph node metas-
tasis and TNM stage of breast cancer, CXCR4 expression was
significantly associated with lymph node metastasis and TNM
stage, and CXCL12 expression was found to be correlated with
TNM stage. A number of functional studies investigating the
influence of CXCR4 expression and activation by its ligand
CXCL12 have recently been performed, revealing that
CXCR4-CXCL12 axis plays an important role in regulating
metastasis of breast cancer to specific organs [23, 25, 34, 35]. A
lot of previous studies indicated that CXCR4 expression played
a crucial role in breast metastasis and correlated with poor
clinical outcome. The previous views also suggested that tumor
cells express high CXCR4, and the metastasis-targeted organs
express high CXCL12, so the tumor cells were attracted to the
ligand in these organs [36]. Given this dichotomy between the
physiologic and pathophysiologic functions of CXCR4, we
hypothesized the constitutive expression of CXCL12 may play
a pivotal role in determining the function of CXCR4 signaling
in the human breast cancer. Wendt et al. reported that the
expression of CXCL12 induces anoikis in colorectal
carcinoma cells, and silencing CXCL12 within colonic
carcinoma cells greatly enhances their metastatic poten-
tial. Their research suggested that physiologic, endogenous
expression of CXCL12 limits tumor metastasis and partici-
pates in the homeostatic turnover of intestinal epithelial cells
[10, 12]. Whether the CXCR4-CXCL12 promotes or limits
the breast cancer metastasis?
To gain a deeper insight into the role of it in breast cancer,
we investigated the CXCL12 and CXCR4 expression in breast
cancer cells MCF-7, MDA-MB-435s, and MDA-MB-231.
The results of Western blot and RT-PCR showed that mRNA
and protein of CXCR4 were observed in MDA-MB-231, and
mRNA and protein of CXCL12 were obvious in MDA-MB-
435s and very weak in MDA-MB-231. So, we picked MDA-
MB-231 to be transfected with CXCL12. Our result showed
that the MDA-MB-231–CXCL12 displayed apparent
CXCL12 expression, whereas MDA-MB-231–ZsGreen1
showed absent CXCL12 expression at the RNA and protein
level. We accessed that the expression of CXCL12 limited the
cellular proliferation and promoted its apoptosis. Interestingly,
Fig. 4 The CXCL12 transfection increased the invasive ability of breast
cancer cell MDA-MB-231. Matrigel invasion assay showed that the
invasive ability of the wild-type MDA-MB-231 (a), MDA-MB-231–
ZsGreen1 (b) and MDA-MB-231–CXCL12 (c) at 48 h after transfection
(d) Number of cells invading onto the lower surfaces of the filter was
counted. Data represented the mean±SD of three independent experi-
ments, *p<0.05 vs. wild-type MDA-MB-231 group, # p<0.05 vs.
MDA-MB-231–ZsGreen1 group
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we also accessed high invasion in MDA-MB-231 coupled
with stable CXCL12 transfection. Are they contradictory?
Our previous research indicated that co-expression of
CXCR4 and CXCL12 was correlated with lymph node me-
tastasis and TNM stage of breast cancer. How do we explain
it? It seemed the limited cellular proliferation and promoted
apoptosis are not opposite to increased invasive ability.
Previous study indicated that the CXCR4-CXCL12 signaling
axis contributes to metastasis and clinical outcomes in breast
cancer. Supporting these data, our clinicopathological study
revealed that patients with co-expression of CXCR4 and
CXCL12 tend to have positive lymph node metastasis and
clinical progression of TNM stage, suggesting that CXCR4-
CXCL12 axis is a significant prognostic marker in breast cancer
patients. The high invasion in MDA-MB-231 coupled with
stable CXCL12 transfection also supported these data. The
limited cellular proliferation and promoted apoptosis doesn’t
opposite to the increased invasive ability. Our experiments about
MDA-MB-231were repeated at least three times independently;
we got the result of the same trend. Wendt et al. found that the
constitutive expression of CXCL12 in human colorectal carci-
noma cells reduced orthotopic tumor formation and inhibited
metastasis in severe combined immunodeficient mice. And
CXCL12 expression induced apoptosis specifically in
nonadherent colorectal carcinoma cells. They considered the
autocrine expression of CXCL12 also accelerated cellular de-
tachment which coupled with breakdown of the focal adhesion
complex and dependent upon alterations in laminin in the ex-
tracellular matrix. The coupling of increased cell shedding and
sensitivity to cell death following detachment from the substra-
tum thoroughly recapitulates the anoikis process of normal
intestinal epithelium [10, 12]. We thought the stably CXCL12
transfection can change the behavioral biology of cancer cells.
The cell proliferation does not equate cell migration. They had
tight relation with each other. The limited cellular proliferation
and promoted apoptosis are not opposite to increased invasive
ability. The stably CXCL12 transfection coupledwith CXCL12-
CXCR4 axis can promote the invasion of MDA-MB-231, in-
creasing the apoptosis of MDA-MB-231 simultaneously. More
powerful and malignant cells survive via CXCL12-CXCR4
axis. Tumor metastasis is the process of natural selection of
cancer cells. It was the survival of the fittest. We speculated that
the CXCL12-CXCR4 axis can promote the natural selection of
breast cancer cell metastasis. The co-expression of CXCR4 and
CXCL12 which correlated with lymph node metastasis and
TNM stage of breast cancer also has a reasonable reason.
In summary, the results of this study suggest that CXCL12-
CXCR4 axis was correlated tightly with breast cancer metas-
tasis. CXCL12-CXCR4 axis can promote the invasion of
MDA-MB-231, increasing the apoptosis of MDA-MB-231
simultaneously. The CXCL12-CXCR4 axis can promote the
natural selection of breast cancer cell metastasis, so the adap-
tive malignant cells can survive. Blocking CXCR4/CXCL12-
induced signaling can slow down the breast cancer growth and
metastasis.
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